{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T08:14:56Z","timestamp":1676103296300},"reference-count":37,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Dalbavancin, a novel lipoglycopeptide, was approved for use in 2014 by regulatory agencies in the United States and Europe for the treatment of skin and skin structure infections. The activity of dalbavancin was also widely assessed by determination of its activity against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Streptococcus pneumoniae<\/jats:named-content>\n            clinical isolates collected from patients on six continents monitored during two time intervals (2011 to 2013 and 2014). A total of 18,186 pneumococcal isolates were obtained from 49 nations and submitted to a monitoring laboratory as part of the SENTRY Antimicrobial Surveillance Program for reference susceptibility testing. The potency of dalbavancin against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. pneumoniae<\/jats:named-content>\n            was consistent across the years that it was monitored, with the MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            being 0.015 and 0.03 \u03bcg\/ml, respectively, and all isolates were inhibited by \u22640.12 \u03bcg\/ml. The activity of dalbavancin was not adversely influenced by nonsusceptibility to \u03b2-lactams (ceftriaxone or penicillin), macrolides, clindamycin, fluoroquinolones, or tetracyclines or multidrug resistance (MDR). Regional variations in dalbavancin activity were not detected, but\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. pneumoniae<\/jats:named-content>\n            strains isolated in the Asia-Pacific region were more likely to be nonsusceptible to penicillin and ceftriaxone as well as to be MDR than strains isolated in North or South America and Europe. Direct comparisons of potency illustrated that dalbavancin (MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.015 and 0.03 \u03bcg\/ml, respectively) was 16-fold or more active than vancomycin (MIC\n            <jats:sub>50<\/jats:sub>\n            , 0.25 \u03bcg\/ml), linezolid (MIC\n            <jats:sub>50<\/jats:sub>\n            , 1 \u03bcg\/ml), levofloxacin (MIC\n            <jats:sub>50<\/jats:sub>\n            , 1 \u03bcg\/ml), ceftriaxone (MIC\n            <jats:sub>90<\/jats:sub>\n            , 1 \u03bcg\/ml), and penicillin (MIC\n            <jats:sub>90<\/jats:sub>\n            , 2 \u03bcg\/ml). In conclusion, dalbavancin had potent and consistent activity against this contemporary (2011 to 2014) collection of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. pneumoniae<\/jats:named-content>\n            isolates.\n          <\/jats:p>","DOI":"10.1128\/aac.00116-16","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T03:45:36Z","timestamp":1458618336000},"page":"3419-3425","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014)"],"prefix":"10.1128","volume":"60","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E.","family":"Schuchert","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01264-06"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310480"},{"key":"e_1_3_2_6_2","volume-title":"DalvanceTM package insert","author":"Allergan","year":"2016","unstructured":"Allergan. 2016. DalvanceTM package insert. Allergan, Parsippany, NJ. Accessed February 2016."},{"key":"e_1_3_2_7_2","unstructured":"EUCAST. 2015. Clinical breakpoints and QC recommendations for the new agents dalbavancin oritavancin and tedizolid. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/New_EUCAST_breakpoints_final.pdf. Accessed August 2015."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr437"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.08.024"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.6.593"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02368-06"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01453-08"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.11.024"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.003"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.002"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.10.031"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5182-5184.2005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/379015"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ982"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312885"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv107"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.05.020"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02557-13"},{"key":"e_1_3_2_26_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_27_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 25th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.6.2795-2796.2003"},{"key":"e_1_3_2_29_2","unstructured":"EUCAST. 2015. Breakpoint tables for interpretation of MICs and zone diameters version 5.0 January. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed January 2015."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02411-06"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00640-06"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.07.008"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.01.017"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00576-06"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1414306"},{"key":"e_1_3_2_37_2","volume-title":"The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae, abstr 1622","author":"Dunne M","year":"2012","unstructured":"Dunne M, Koeth LM, Windau AR. 2012. The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae, abstr 1622. IDWeek, San Diego, CA."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv357"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00116-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00116-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:46:23Z","timestamp":1645476383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00116-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1128\/AAC.00116-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00116-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"2016-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}